We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Identification of Rickettsial Biomarker Facilitates Early Diagnosis of Tick-borne Spotted Fevers

By LabMedica International staff writers
Posted on 27 Jan 2020
Print article
Image: Photomicrograph of Rickettsia conorii in Vero cells (red rods; magnification ×1,000) (Photo courtesy of Wikimedia Commons)
Image: Photomicrograph of Rickettsia conorii in Vero cells (red rods; magnification ×1,000) (Photo courtesy of Wikimedia Commons)
A protein biomarker has been identified that enables the rapid and specific early diagnosis of tick-borne rickettsial diseases such as Rocky Mountain spotted fever and Mediterranean spotted fever.

The causative agent of these diseases is Rickettsia conorii, a Gram-negative, obligate intracellular bacterium of the genus Rickettsia. It is a member of the spotted fever group and the most geographically dispersed species in the group, recognized in most of the regions bordering on the Mediterranean Sea and Black Sea: Israel, Kenya, and other parts of North, Central, and South Africa, and India.

R. conorii causes the human disease called boutonneuse fever, Mediterranean spotted fever, Israeli tick typhus, Astrakhan spotted fever, Kenya tick typhus, Indian tick typhus, or other names that designate the locality of occurrence while having distinct clinical features. The disease presents as an eschar (dry, dark scab), acute fever, headache, and maculopapular rash. After entering the body, rickettsiae can cause vascular leakage, such as pulmonary or cerebral edema. The prevailing vector is the brown dog tick, Rhipicephalus sanguineus.

Since there are no available tests for diagnosis of early R. conorii infection, Mediterranean spotted fever is often not diagnosed and left untreated, resulting in significant mortality. To address this critical need, investigators at the University of Texas Medical Branch (Galveston, USA) applied a quantitative proteomics approach for analyzing the molecules secreted by primary human umbilical vein endothelial cells that had been infected with R. conorii.

Results revealed that of the 104 proteins whose abundance changed significantly in the R. conorii–infected human umbilical vein endothelial cells’ secretome (the set of proteins expressed by an organism and secreted into the extracellular space), 46 proteins were up-regulated: 45 were host secreted proteins (including cytokines), and one was a rickettsial protein, the putative N-acetylmuramoyl-l-alanine amidase RC0497.

RC0497 is an enzyme that hydrolyzes the link between N-acetylmuramoyl residues and L-amino acid residues in certain cell-wall glycopeptides. Proteins with sequence highly homologous to RC0497 were found to be shared by many species of the spotted fever group rickettsiae, but not typhus group rickettsiae.

The investigators developed an immunoprecipitation (IP) enrichment-selected reaction monitoring (SRM) assay to detect the small amount of circulating RC0497, and this assay was validated as a diagnostic approach in a cohort of humans presenting with acute rickettsial infections.

"The detection of RC0497 has the potential to diagnosis a wide variety of rickettsial spotted fever infections, including Rocky Mountain spotted fever," said senior author Dr. Yingxin Zhao, assistant professor of internal medicine at the University of Texas Medical Branch. "The rickettsioses represent an important unmet need in human and veterinary medicine. Rickettsioses are a spectrum of potentially lethal diseases whose diagnosis and definitive treatment require a high index of suspicion."

The study was published in the January 16, 2020, online edition of the American Journal of Pathology.

Related Links:
University of Texas Medical Branch

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more